You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 7,585,837

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,585,837
Title:Reversible pegylated drugs
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
Inventor(s): Shechter; Yoram (Rehovot, IL), Fridkin; Matityahu (Rehovot, IL), Tsubery; Haim (Elad, IL)
Assignee: Yeda Research and Development Co. Ltd. (Rehovot, IL)
Application Number:11/244,402
Patent Claims:see list of patent claims

Details for Patent 7,585,837

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Lilly HUMULIN R insulin recombinant human INJECTABLE;INJECTION 018780 001 1982-12-02   Start Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) 2023-04-08 RX search
Lilly HUMULIN R KWIKPEN insulin human SOLUTION;SUBCUTANEOUS 018780 002 1982-12-02   Start Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) 2023-04-08 RX search
Lilly HUMULIN R insulin human SOLUTION;SUBCUTANEOUS 018780 004 1982-12-02   Start Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) 2023-04-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.